Skip to main content
SpringerLink
Log in

Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells

  • Short communication
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Multidrug resistance (MDR) is the phenomenon in which cultured tumor cells selected for resistance to one chemotherapeutic agent simultaneously acquire resistance to several apparently unrelated drugs. MDR in tumor cells is associated with the over-expression of P-glycoprotein, an ATP-dependent cell-membrane transport molecule. P-glycoprotein is also expressed in several normal tissues but its physiological role(s) is unknown. We recently observed that a hierarchy of MDR-like activity exists among human peripheral blood lymphocytes in the order CD8>CD4>CD20 (cytoxic/suppressor T cells, helper T cells and B cells respectively). In this study, we report that natural killer (NK) cells also express MDR-like activity. This activity could be inhibited with verapamil or solutol HS-15, two agents that reverse MDR in tumor cells. These, and four additional reversing agents, were used to investigate the possible role of P-glycoprotein in NK cells. We observed that at 10% of their IC50, five of six reversing agents inhibited NK-cell-mediated cytotoxicity; at higher (but non-toxic) doses, all six agents were inhibitory. These data suggest that NK-cell-mediated cytotoxicity may require the functional expression of an efflux molecule similar or identical to P-glycoprotein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM (1985) Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 11: 117

    Google Scholar 

  2. Chaudhary PM, Roninson IB (1991) Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic cells. Cell 66: 85

    Google Scholar 

  3. Chong AS-F, Hersh EM, Grimes WJ (1988) Blocking of lymphokine activated killer (LAK) cell mediated cytotoxicity by cell-sized beads bearing tumor cell proteins. J Immunol 141: 4418

    Google Scholar 

  4. Coon JS, Knudson W, Clodfelter K, Lu B, Weinstein RS (1991) Solutol HS 15, Nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Res 51: 897

    Google Scholar 

  5. Coon JS, Wang Y, Bines S, Markham PM, Chong AS-F, Gebel HM (1991) Multidrug resistance activity in human lymphocytes. Hum Immunol 32: 134

    Google Scholar 

  6. Cordon-Cardo C, O'Brien JP, Casais D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood brain barrier sites. Proc Natl Acad Sci USA 86: 695

    Google Scholar 

  7. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor DW, Miller TP, Salmon SE (1989) Drug resistance in multiple myeloma and non-Hodgkins lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415

    Google Scholar 

  8. Darzynkiewicz Z, Trangonos F, Staino-Coico L, Kapuscinski J, Melamed MR (1982) Interactions of rhodamine 123 with living cells studied by flow cytometry. Cancer Res 42: 799

    Google Scholar 

  9. Duvie BG, Dalton WS (1988) Reversal of multidrug resistance in multiple myeloma with verapamil. Br J Hematol 68: 203

    Google Scholar 

  10. Endicott JA. Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137

    Google Scholar 

  11. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987) Expression of a multi-drug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265

    Google Scholar 

  12. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987) Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug resistance gene. J Clin Oncol 5: 1922

    Google Scholar 

  13. Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155

    Google Scholar 

  14. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S-I, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116

    Google Scholar 

  15. Gros P, Ben Neriah Y, Croop JM, Housman DE (1986) Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323: 728

    Google Scholar 

  16. Juranka PF, Zastawny RL, Ling V (1989) P-glycoprotein: multidrug-resistance and a superfamily of membrane associated transport proteins. Faseb J 3: 2583

    Google Scholar 

  17. Mechetner EB, Ronison IB (1992) Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 89: 5824

    Google Scholar 

  18. Neyfakh AA, Serpinskaya AS, Chervonsky AV, Apasov SG, Kazarov AR (1989) Multi-drug resistance phenotype of a sub-population of T-lymphocytes without drug selection. Exp Cell Res 185: 496

    Google Scholar 

  19. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V (1985) Amplification of P-glycoprotein genes in multidrug-resistant mammalian cells. Nature 316: 817

    Google Scholar 

  20. Rivoltini L, Colombo MP, Supino R, Ballinari D, Tsuruo T, Parmiani G (1990) Modulation of multidrug resistance by verapamil or mdrl anti-sense oligonucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. Int J Cancer 46: 727

    Google Scholar 

  21. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S (1988) Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK16. Cancer Res 48: 1926

    Google Scholar 

  22. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735

    Google Scholar 

  23. Trinchieri G (1989) Biology of natural killer cells. Adv Immunol 47: 187

    Google Scholar 

  24. Tsuruo T (1991) Reversal of multidrug resistance by calcium channel blockers and other agents. In: Roninson IB (ed) Molecular and cellular biology of multidrug resistance in tumor cells. Plenum, New York, pp 349–372

    Google Scholar 

  25. Ueda K, Cornwell MM, Gottesman MM, Pastan I, Roninson IB, Ling V, Riordan JR (1986) The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 141: 956

    Google Scholar 

  26. Woods G, Lund LA, Naik M, Ling V, Ochi A (1988) Resistance of multidrug resistant lines to natural killer-like cell-mediated cytotoxicity. Faseb J 2: 2791

    Google Scholar 

  27. Yanovich S, Haal RE, Weinert C (1986) Resistance to natural killer-cell-mediated cytolysis by a pleiotropic drug-resistant human erythroleukemia (K562) cell line. Cancer Res 46: 4511

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Surgery, Rush-Presbyterian — St. Luke's Medical Center, Chicago, USA

    Anita S. -F. Chong, Howard M. Gebel, Steven D. Bines & John S. Coon

  2. Department of Immunology/Microbiology, Rush-Presbyterian — St. Luke's Medical Center, 1653 W. Congress Parkway, 60 612, Chicago, IL, USA

    Anita S. -F. Chong, Penelope N. Markham, Howard M. Gebel & John S. Coon

  3. Department of OCLS Immunology, Rush-Presbyterian — St. Luke's Medical Center, Chicago, USA

    Howard M. Gebel & John S. Coon

  4. Department of Pathology, Rush-Presbyterian — St. Luke's Medical Center, Chicago, USA

    John S. Coon

Authors
  1. Anita S. -F. Chong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Penelope N. Markham
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Howard M. Gebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steven D. Bines
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John S. Coon
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported in part by grants from the National Cancer Institute (CA 57 470), the American Cancer Association — Illinois Division (no. 91-48), The Arthur Andersen Foundation and the Rayman, Freidman, Ditore and Rosenmutter Funds.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chong, A.S.F., Markham, P.N., Gebel, H.M. et al. Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells. Cancer Immunol Immunother 36, 133–139 (1993). https://doi.org/10.1007/BF01754414

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01754414

Key words

Search

Navigation